FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048490260> ?p ?o ?g. }

• W3048490260 abstract "Introduction At present, there is no approved medical treatment option for patients with non-functioning pituitary adenoma. A number of open-label studies suggest that treatment with somatostatin analogues may prevent tumour progression. In vivo somatostatin receptor imaging using 68 Ga-DOTATATE PET (PET, positron emission tomography) could help in preselecting patients potentially responsive to treatment. Our aim is to investigate the effect of the somatostatin analogue lanreotide as compared with placebo on tumour size in patients with a 68 Ga-DOTATATE PET-positive non-functioning pituitary macroadenoma (NFMA). Methods and analysis The GALANT study is a multicentre, randomised, double-blind, placebo-controlled trial in adult patients with a suprasellar extending NFMA. Included patients undergo a 68 Ga-DOTATATE PET/CT of the head and tracer uptake is assessed after coregistration with pituitary MRI. Forty-four patients with a 68 Ga-DOTATATE PET-positive NFMA are randomised in a 1:1 ratio between lanreotide 120 mg or placebo, both administered as subcutaneous injections every 28 days for 72 weeks. The primary outcome is the change in cranio-caudal tumour diameter on pituitary MRI after treatment. Secondary outcomes are change in tumour volume, time to tumour progression, change in quality of life and number of adverse events. Final results are expected in the second half of 2021. Ethics and dissemination The study protocol has been approved by the Medical Research Ethics Committee of the Academic Medical Centre (AMC) of the Amsterdam University Medical Centres and by the Dutch competent authority. It is an investigator-initiated study with financial support by Ipsen Farmaceutica BV. The AMC, as sponsor, remains owner of all data. Results will be submitted for publication in a peer-reviewed journal. Trial registration number NL5136 (Netherlands Trial Register); pre-recruitment." @default.
• W3048490260 created "2020-08-18" @default.
• W3048490260 creator A5015849613 @default.
• W3048490260 creator A5024309954 @default.
• W3048490260 creator A5032760472 @default.
• W3048490260 creator A5037396004 @default.
• W3048490260 creator A5038606885 @default.
• W3048490260 creator A5041100881 @default.
• W3048490260 creator A5042807722 @default.
• W3048490260 creator A5050665753 @default.
• W3048490260 creator A5053147277 @default.
• W3048490260 creator A5063984039 @default.
• W3048490260 creator A5073880325 @default.
• W3048490260 creator A5084528917 @default.
• W3048490260 creator A5086710202 @default.
• W3048490260 date "2020-08-01" @default.
• W3048490260 modified "2023-10-16" @default.
• W3048490260 title "The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size" @default.
• W3048490260 cites W1584743295 @default.
• W3048490260 cites W1717165705 @default.
• W3048490260 cites W1777965455 @default.
• W3048490260 cites W1975786744 @default.
• W3048490260 cites W1976609439 @default.
• W3048490260 cites W1988301094 @default.
• W3048490260 cites W1994717163 @default.
• W3048490260 cites W2005674134 @default.
• W3048490260 cites W2009656180 @default.
• W3048490260 cites W2016219575 @default.
• W3048490260 cites W2031565988 @default.
• W3048490260 cites W2036437059 @default.
• W3048490260 cites W2037053913 @default.
• W3048490260 cites W2038843944 @default.
• W3048490260 cites W2051091626 @default.
• W3048490260 cites W2053692867 @default.
• W3048490260 cites W2059118346 @default.
• W3048490260 cites W2059432601 @default.
• W3048490260 cites W2065593787 @default.
• W3048490260 cites W2065840495 @default.
• W3048490260 cites W2065974896 @default.
• W3048490260 cites W2085075503 @default.
• W3048490260 cites W2096024465 @default.
• W3048490260 cites W2102471539 @default.
• W3048490260 cites W2108052917 @default.
• W3048490260 cites W2109699675 @default.
• W3048490260 cites W2119094244 @default.
• W3048490260 cites W2135049144 @default.
• W3048490260 cites W2150362274 @default.
• W3048490260 cites W2160267164 @default.
• W3048490260 cites W2166023752 @default.
• W3048490260 cites W2169967426 @default.
• W3048490260 cites W2171811563 @default.
• W3048490260 cites W2274885851 @default.
• W3048490260 cites W2520505463 @default.
• W3048490260 cites W2572399935 @default.
• W3048490260 cites W2586116929 @default.
• W3048490260 cites W2611438744 @default.
• W3048490260 cites W2789918217 @default.
• W3048490260 cites W2794002252 @default.
• W3048490260 cites W2938057722 @default.
• W3048490260 cites W71229122 @default.
• W3048490260 doi "https://doi.org/10.1136/bmjopen-2020-038250" @default.
• W3048490260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7430490" @default.
• W3048490260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32792446" @default.
• W3048490260 hasPublicationYear "2020" @default.
• W3048490260 type Work @default.
• W3048490260 sameAs 3048490260 @default.
• W3048490260 citedByCount "2" @default.
• W3048490260 countsByYear W30484902602021 @default.
• W3048490260 countsByYear W30484902602022 @default.
• W3048490260 crossrefType "journal-article" @default.
• W3048490260 hasAuthorship W3048490260A5015849613 @default.
• W3048490260 hasAuthorship W3048490260A5024309954 @default.
• W3048490260 hasAuthorship W3048490260A5032760472 @default.
• W3048490260 hasAuthorship W3048490260A5037396004 @default.
• W3048490260 hasAuthorship W3048490260A5038606885 @default.
• W3048490260 hasAuthorship W3048490260A5041100881 @default.
• W3048490260 hasAuthorship W3048490260A5042807722 @default.
• W3048490260 hasAuthorship W3048490260A5050665753 @default.
• W3048490260 hasAuthorship W3048490260A5053147277 @default.
• W3048490260 hasAuthorship W3048490260A5063984039 @default.
• W3048490260 hasAuthorship W3048490260A5073880325 @default.
• W3048490260 hasAuthorship W3048490260A5084528917 @default.
• W3048490260 hasAuthorship W3048490260A5086710202 @default.
• W3048490260 hasBestOaLocation W30484902601 @default.
• W3048490260 hasConcept C126322002 @default.
• W3048490260 hasConcept C142724271 @default.
• W3048490260 hasConcept C197934379 @default.
• W3048490260 hasConcept C204787440 @default.
• W3048490260 hasConcept C27081682 @default.
• W3048490260 hasConcept C2775842073 @default.
• W3048490260 hasConcept C2776297358 @default.
• W3048490260 hasConcept C2777428134 @default.
• W3048490260 hasConcept C2777433750 @default.
• W3048490260 hasConcept C2779318953 @default.
• W3048490260 hasConcept C2779609023 @default.
• W3048490260 hasConcept C2781025020 @default.
• W3048490260 hasConcept C2984496839 @default.
• W3048490260 hasConcept C2989005 @default.
• W3048490260 hasConcept C71315377 @default.
• W3048490260 hasConcept C71924100 @default.

• next